KR20210143037A - Fermented black ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof - Google Patents
Fermented black ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof Download PDFInfo
- Publication number
- KR20210143037A KR20210143037A KR1020200059945A KR20200059945A KR20210143037A KR 20210143037 A KR20210143037 A KR 20210143037A KR 1020200059945 A KR1020200059945 A KR 1020200059945A KR 20200059945 A KR20200059945 A KR 20200059945A KR 20210143037 A KR20210143037 A KR 20210143037A
- Authority
- KR
- South Korea
- Prior art keywords
- black ginseng
- fermented
- ginseng composition
- fermented black
- yeast
- Prior art date
Links
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 116
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 116
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 116
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 53
- 239000011707 mineral Substances 0.000 title claims abstract description 53
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 48
- 238000000855 fermentation Methods 0.000 title claims abstract description 39
- 230000004151 fermentation Effects 0.000 title claims abstract description 39
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- 235000008216 herbs Nutrition 0.000 title abstract description 7
- 244000131316 Panax pseudoginseng Species 0.000 title 1
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 15
- 230000001965 increasing effect Effects 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 7
- 238000010025 steaming Methods 0.000 claims abstract description 7
- 230000036541 health Effects 0.000 claims abstract description 4
- 241000208340 Araliaceae Species 0.000 claims abstract 20
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 42
- 241000411851 herbal medicine Species 0.000 claims description 27
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 11
- 229910052791 calcium Inorganic materials 0.000 claims description 11
- 239000011575 calcium Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 8
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 8
- 229940010454 licorice Drugs 0.000 claims description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 239000010949 copper Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 6
- 239000011669 selenium Substances 0.000 claims description 6
- 229910052711 selenium Inorganic materials 0.000 claims description 6
- 241000287828 Gallus gallus Species 0.000 claims description 5
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 244000061520 Angelica archangelica Species 0.000 claims description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 3
- 241000235070 Saccharomyces Species 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 235000006533 astragalus Nutrition 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- 239000011733 molybdenum Substances 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- QOMBXPYXWGTFNR-KRPFXEAISA-N (20E)-Ginsenoside F4 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\C/C=C(\C)/C)/C)CC3)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 QOMBXPYXWGTFNR-KRPFXEAISA-N 0.000 claims 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 claims 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims 1
- 241001061264 Astragalus Species 0.000 claims 1
- LDWYLENMYNXSBM-UHFFFAOYSA-N Ginsenoside F4 Natural products CC1OC(OC2C(O)C(O)C(CO)OC2OC3CC4(C)C(CC(O)C5C(CCC45C)C(=C/CC=C(C)C)C)C6(C)CCC(O)C(C)(C)C36C)C(O)C(O)C1O LDWYLENMYNXSBM-UHFFFAOYSA-N 0.000 claims 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims 1
- ZVTVWDXRNMHGNY-JOGTXEPTSA-N Ginsenoside Rg6 Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](C(=C)CC/C=C(\C)/C)CC3)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 ZVTVWDXRNMHGNY-JOGTXEPTSA-N 0.000 claims 1
- OZTXYFOXQFKYRP-RISAHGKBSA-N Ginsenoside Rh4 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\C/C=C(\C)/C)/C)CC3)C1 OZTXYFOXQFKYRP-RISAHGKBSA-N 0.000 claims 1
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 claims 1
- 210000004233 talus Anatomy 0.000 claims 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 229930182494 ginsenoside Natural products 0.000 abstract description 16
- 239000004480 active ingredient Substances 0.000 abstract description 13
- 229940089161 ginsenoside Drugs 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 5
- 239000013543 active substance Substances 0.000 abstract description 2
- 240000004371 Panax ginseng Species 0.000 description 95
- 235000010755 mineral Nutrition 0.000 description 42
- 229930182490 saponin Natural products 0.000 description 9
- 150000007949 saponins Chemical class 0.000 description 9
- 235000017709 saponins Nutrition 0.000 description 9
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 8
- 241000202807 Glycyrrhiza Species 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 235000002789 Panax ginseng Nutrition 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229940091258 selenium supplement Drugs 0.000 description 5
- 241001474374 Blennius Species 0.000 description 4
- YJHVMPKSUPGGPZ-UHFFFAOYSA-N Dihydro-beta-eudesmol Natural products C1CC(C(C)(C)O)CC2C(C)CCCC21C YJHVMPKSUPGGPZ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 description 4
- XFSVWZZZIUIYHP-UHFFFAOYSA-N beta-Eudesmol Natural products CC(C)(O)C1CCC2CCCC(=C)C2C1 XFSVWZZZIUIYHP-UHFFFAOYSA-N 0.000 description 4
- BOPIMTNSYWYZOC-VNHYZAJKSA-N beta-eudesmol Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(C)(O)C)CC[C@]21C BOPIMTNSYWYZOC-VNHYZAJKSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 4
- 239000006049 herbal material Substances 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 3
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000037093 Menstruation Disturbances Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 3
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- LLKXNMNOHBQSJW-UHFFFAOYSA-N Elemol Natural products CCC(=C)C1CC(C=CC1(C)C)C(C)(C)O LLKXNMNOHBQSJW-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- 244000236658 Paeonia lactiflora Species 0.000 description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- PVLHOJXLNBFHDX-XHJPDDKBSA-N Panaxadiol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(CC[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 PVLHOJXLNBFHDX-XHJPDDKBSA-N 0.000 description 2
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 2
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 2
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 2
- -1 analgesic Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229930007050 cineol Natural products 0.000 description 2
- 229960005233 cineole Drugs 0.000 description 2
- GFJIQNADMLPFOW-UHFFFAOYSA-N cis-Elemol Natural products CC(=C)C1CC(C(C)(C)O)CCC1(C)C=C GFJIQNADMLPFOW-UHFFFAOYSA-N 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- 229960000355 copper sulfate Drugs 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- GFJIQNADMLPFOW-VNHYZAJKSA-N elemol Chemical compound CC(=C)[C@@H]1C[C@H](C(C)(C)O)CC[C@@]1(C)C=C GFJIQNADMLPFOW-VNHYZAJKSA-N 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- OLOOJGVNMBJLLR-UHFFFAOYSA-N imperatorin Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OCC=C(C)C OLOOJGVNMBJLLR-UHFFFAOYSA-N 0.000 description 2
- XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000009616 inductively coupled plasma Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 229960003390 magnesium sulfate Drugs 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940071440 soy protein isolate Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 241001350919 Cinnamomum loureiroi Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- UXDIXFDKSPCUIX-AXFHLTTASA-N Cnidilide Chemical compound C1=CCC[C@@H]2[C@H](CCCC)OC(=O)[C@@H]21 UXDIXFDKSPCUIX-AXFHLTTASA-N 0.000 description 1
- 241000533367 Cnidium officinale Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CUKSFECWKQBVED-INIZCTEOSA-N Decursin Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-INIZCTEOSA-N 0.000 description 1
- BGXFQDFSVDZUIW-UHFFFAOYSA-N Decursinol Natural products O1C(=O)C=CC2=C1C=C1OC(C)(C)C(O)CC1=C2 BGXFQDFSVDZUIW-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- CUKSFECWKQBVED-UHFFFAOYSA-N Grandivittin Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-UHFFFAOYSA-N 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- UPJFTVFLSIQQAV-KOLCDFICSA-N Neocnidilide Chemical compound C1CC[C@H]2[C@H](CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-KOLCDFICSA-N 0.000 description 1
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Neocnidilide Natural products C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 description 1
- HXCGUCZXPFBNRD-DNLMCPORSA-N Nodakenin Chemical compound CC(C)([C@@H]1OC2=CC=3OC(=O)C=CC=3C=C2C1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HXCGUCZXPFBNRD-DNLMCPORSA-N 0.000 description 1
- HXCGUCZXPFBNRD-QVYYAULWSA-N Nodakenin Natural products O(C(C)(C)[C@@H]1Oc2c(cc3c(OC(=O)C=C3)c2)C1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HXCGUCZXPFBNRD-QVYYAULWSA-N 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 239000008989 cinnamomi cortex Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- UXDIXFDKSPCUIX-UHFFFAOYSA-N condilide Natural products C1=CCCC2C(CCCC)OC(=O)C21 UXDIXFDKSPCUIX-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001893 coumarin derivatives Chemical class 0.000 description 1
- JXZWWIMXTVJNSF-UHFFFAOYSA-N decursin Natural products CC(=CC(=O)OC1Oc2cc3OC(=O)C=Cc3cc2CC1(C)C)C JXZWWIMXTVJNSF-UHFFFAOYSA-N 0.000 description 1
- BGXFQDFSVDZUIW-LBPRGKRZSA-N decursinol Chemical compound O1C(=O)C=CC2=C1C=C1OC(C)(C)[C@@H](O)CC1=C2 BGXFQDFSVDZUIW-LBPRGKRZSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001930 leg bone Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- HXCGUCZXPFBNRD-UHFFFAOYSA-N nodakenine Natural products C1C2=CC=3C=CC(=O)OC=3C=C2OC1C(C)(C)OC1OC(CO)C(O)C(O)C1O HXCGUCZXPFBNRD-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000036435 stunted growth Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/10—General methods of cooking foods, e.g. by roasting or frying
- A23L5/13—General methods of cooking foods, e.g. by roasting or frying using water or steam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 생약재 미네랄 효모 발효액을 이용하여 제조되는 발효 흑삼 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a fermented black ginseng composition prepared by using a herbal mineral yeast fermentation broth and a method for producing the same.
인삼은 오래전부터 사용되어온 대표적인 자양강장제이며, 그 함유 성분에 대한 약리학적 연구가 많이 이루어지고 있다. 인삼은 고지혈증의 개선, 간 기능 강화, 항스트레스 효과, 면역 증강, 뇌기능 개선, 항암 효과 등 다양한 효능을 나타내며, 인체의 항상성을 유지하는 역할을 한다. 특히 인삼 사포닌은 다른 식물에서 발견되는 사포닌과는 다른 특이한 화학구조를 가지고 있으며 약리효능도 특이하여 인삼(Ginseng)과 배당체(Glycoside)란 의미로 '진세노사이드(Ginsenoside)'라 불린다. Ginseng is a representative nourishing and tonic agent that has been used for a long time, and many pharmacological studies have been conducted on its ingredients. Ginseng exhibits various effects such as improvement of hyperlipidemia, enhancement of liver function, anti-stress effect, immune enhancement, improvement of brain function, and anti-cancer effect, and plays a role in maintaining homeostasis of the human body. In particular, ginseng saponin has a unique chemical structure that is different from saponin found in other plants, and has a unique pharmacological effect.
이들 인삼사포닌은 대체로 수삼에 존재하는 것으로 알려져 있으나, 특정한 일부 인삼사포닌은 가공된 인삼에만 존재하는 것으로 알려져 있다. 최근에는 이들 가공된 인삼에만 존재하는 인삼사포닌의 함량을 더욱 높이기 위한 많은 연구가 진행되었다.These ginseng saponins are generally known to exist in fresh ginseng, but some specific ginseng saponins are known to exist only in processed ginseng. Recently, many studies have been conducted to further increase the content of ginseng saponins, which are only present in these processed ginseng.
인삼류 내에 함유된 진세노사이드는 크게 파낙사디올계(PD)와 흥분작용을 하는 파낙사트리올계(PT)로 구분할 수 있으며, 주요 진세노사이드의 효능을 아래 표 1에 정리하여 나타내었다.Ginsenosides contained in ginseng can be largely divided into panaxadiol (PD) and excitatory panaxatriol (PT), and the effects of major ginsenosides are summarized in Table 1 below.
특히 흑삼은 수회 증숙 및 건조과정을 거쳐 인삼이 검은 색으로 변한 삼을 의미하는 것으로서, 수회 증식 및 건조과정을 거치면서 기본적으로 존재하는 인삼사포닌이 소실되지 않을 뿐만 아니라, 가공된 인삼에만 존재하는 인삼사포닌의 함량이 증진되는 것으로 알려져 있어, 이러한 흑삼을 보다 효과적으로 제조하는 방법에 대한 연구가 활발하게 수행되고 있다.In particular, black ginseng refers to ginseng in which ginseng has turned black after several times of steaming and drying. In addition, ginseng saponins that are basically present are not lost through several times of proliferation and drying, and ginseng that exists only in processed ginseng. It is known that the content of saponin is increased, so research on a method for producing such black ginseng more effectively is being actively conducted.
즉 흑삼을 어떤 조건에서 찌고 말리는 과정을 반복하느냐에 따라 흑삼의 유효성분(사포닌)의 함량이 크게 달라지므로 흑삼 내 진세노사이드의 함량을 보다 끌어올리기 위해 생약재를 추가하거나 추가적인 물질을 첨가하는 등 다양한 시도가 이루어지고 있다.That is, the content of the active ingredient (saponin) of black ginseng varies greatly depending on the conditions under which steaming and drying of black ginseng is repeated. is being done
백복령(Poria cocas)은 소나무를 베어낸 그루터기 흙속에 기생하는 백색 또는 회백색의 균사체로서, 복용시 기혈이 상통하여 두발에 윤기가 생기고 탈모현상이 완화되거나 치유되며, 자양강장 효과가 우수하여 장복시 몸이 가벼워지고 피부를 맑고 윤택하게 하는 효능이 있는 것으로 알려져 있다. Poria cocas is a white or grayish-white mycelium parasitic in the soil of a pine tree stump. When taken, the qi and blood are common, giving the hair a shine, alleviating or healing hair loss, and has excellent nourishing and tonic properties. It is known to have the effect of lightening and brightening the skin.
감초(Glycyrrhiza uralensis)는 한방에서 없어서는 안 될 기본적인 유용한 약재로 사용되어 오고 있다. 감초는 인체의 비위를 건강하게 할 뿐만 아니라 오장육부의 한열사기를 치료하고 근골을 튼튼하게 할 뿐만 아니라 각종 종기와 부스럼 등을 치료하고 온갖 약초의 독을 해독시키는 작용을 가지며 폐의 활동을 돕고 청열해독의 효과가 큰 약초이다. 경련이나 통증 등 급한 증상을 낫게 하고 열독을 없앨 뿐 아니라, 염증을 가라앉혀 주므로 인후염이나 종기가 났을 때 사용하면 효과가 있다. 또한, 감초의 주요 성분 중 하나인 글리시리진은 감초에 독특한 단맛을 부여하는 성분이다. Glycyrrhiza uralensis (Glycyrrhiza uralensis) has been used as a basic useful medicine indispensable in oriental medicine. Licorice not only makes the stomach of the human body healthy, but it also treats cold sores in the intestines and intestines, strengthens muscles and bones, as well as treats various boils and bruises, detoxifies the poison of all kinds of medicinal herbs, helps the lungs and helps with cooling and fever. It is a medicinal herb with great detoxification effect. It relieves acute symptoms such as cramps or pain, eliminates heat poisoning, and relieves inflammation, so it is effective when used in sore throats or boils. In addition, glycyrrhizin, one of the main components of licorice, is a component that imparts a unique sweetness to licorice.
숙지황(Rehmanniae radix preparata)은 성질이 따뜻하고, 맛은 달고 약간 쓰며 독이 없다. 생리불순, 허약체질, 어린이의 발육 부진, 치매, 조루증, 발기부전 등에 사용되고 있으며 혈액 순환을 개선시켜 여러 만성 질환의 말초미세 순환을 개선시키는 효과, 혈중 과산화물 제거효소, 글루타티온 산화효소의 증가와 지질과산화의 억제, 면역증가 효과, 항암작용, 섬유소용해계의 활성증가, 폴리브렌에 의해 유도되는 적혈구 집괴의 감소, 적혈구 변형능과 ATP 함량의 증가 등이 보고되고 있다. Rehmanniae radix preparata is warm in nature, sweet in taste, slightly bitter, and non-toxic. It is used for irregular menstruation, weak constitution, stunted growth in children, dementia, premature ejaculation, and erectile dysfunction. It improves blood circulation and improves peripheral microcirculation in various chronic diseases. Inhibition of the immune system, the effect of increasing immunity, anticancer action, increase in fibrinolytic system activity, reduction of polybrene-induced red blood cell aggregation, and increase in red blood cell deformability and ATP content have been reported.
백작약(Paeoniae radix alba)은 맛이 쓰고 시며 성질은 약간 차다. 혈액을 풍부하게 하고 통증과 땀을 멎게 하며 지혈하고 간화(肝火)를 없애며 소변이 잘 나오게 한다. 유효성분 중 하나인 페오니플로린 성분은 진정 작용, 진통 작용, 진경 작용, 해열 작용, 소염 작용, 항궤양 작용, 혈압강하 작용, 관상혈관 확장 작용을 나타내고, 페오놀 성분은 진정 작용, 해열 작용, 진통 작용, 진경 작용, 소염 작용, 지혈 작용을 나타낸다. 백작약은 항균 작용도 나타낸다. 혈허증, 혈허로 인한 복통, 위장 경련으로 인한 복통, 팔다리가 오그라들며 아픈 데, 신경통, 류머티스성 관절염, 생리통, 흉통, 간화로 머리가 아프고 어지러운 데, 신경쇠약, 월경이 많은 데, 부정자궁출혈, 저절로 땀이 나는 데, 식은땀, 이질, 대하증, 뾰루지에 쓴다. Paeoniae radix alba is bitter in taste and slightly cold in nature. It enriches blood, stops pain and sweat, stops hemostasis, eliminates liver fire, and makes urine come out well. One of the active ingredients, pheniflorin, has sedative, analgesic, antispasmodic, antipyretic, anti-inflammatory, anti-ulcer, blood pressure lowering, and coronary vasodilation effects. It exhibits analgesic action, antispasmodic action, anti-inflammatory action, and hemostatic action. Peony also exhibits antibacterial action. Hemorrhagic disease, abdominal pain due to blood clots, abdominal pain due to gastrointestinal spasm, cramping pain in arms and legs, neuralgia, rheumatoid arthritis, menstrual pain, chest pain, headache and dizziness due to liver cirrhosis, nervous breakdown, frequent menstruation, irregular uterine bleeding , For spontaneous sweating, it is used for cold sweat, dysentery, dysentery, and pimples.
육계(Cinnamomi cortex)는 육계나무(Cinnamomum loureirii) 또는 계피나무(Cinnamomum cassia)의 줄기 및 가지 수피로서, 주성분으로는 신남알데하이드(Cinnamicaldehyde), 캄펜(Camphene), 치네올(Cineol), 리날로올(Linalool), 유게놀(Eugenol) 등이 있으며 진정, 항균 등의 효능이 있다고 알려져 있다. Cinnamomi cortex is the trunk and branch bark of Cinnamomum loureirii or Cinnamomum cassia , and the main components are cinnamicaldehyde, camphene, cineol, linalool (Cineol), Linalool) and Eugenol are known to have soothing and antibacterial effects.
백출(Atractylodis rhizoma)은 주요성분으로 아트랙틸론(Atractylone), 아트랙틸레놀라이드(Atractylenolide) I, Ⅱ, Ⅲ, 베타-에우데스몰(ß-Eudesmol), 하이네솔(Hynesol)등이 알려져 있다. 쓴맛과 단맛이 나는 국화과의 뿌리식물로, 비장의 기를 붇돋아 주고 건위작용, 이뇨작용, 자양작용, 진정작용 등의 효과가 있다.Baekchul ( Atractylodis rhizoma ) is known as attractylone (Atractylone), attractylenolide (Atractylenolide) I, Ⅱ, Ⅲ, beta-eudesmol (ß-Eudesmol), hynesol (Hynesol), etc. as a major component. It is a root plant of the Asteraceae family with a bitter and sweet taste. It swells the spleen and has effects such as gastric, diuretic, nourishing, and sedative.
천궁(Cnidium officinale)은 방향성 정유를 다량 함유하고 있어서 냄새가 좋다. 주성분은 크니딜라이드(cnidilide), 네오크니딜라이드(neocnidilide), 리구스틸라이드(ligustilide) 등이 있다. 어린순은 나물로 먹고 뿌리줄기는 건조시켜 약재로 이용한다. 약성이 온화하고 맛이 시어서 체내에 들어가서는 혈액순환을 왕성하게 해주고 통증을 가라앉히는 진통효과가 있다. 그러므로 두통에도 자주 응용된다. 부인에게 있어서는 월경불순·월경통·산후복통과 어지러운 증상을 없애준다. 또, 간장의 기능을 활성화시켜 주고 빈혈에 복용하면 조혈작용으로 효험을 얻게 된다. 그리고 심장근육의 수축부전으로 인한 심장 부위의 통증에도 증상을 호전시키고 있다. 허리와 다리의 골격이 약하고 근육에 경련을 자주 일으키는 사람이 복용하면 그와 같은 증상이 개선된다. Cnidium officinale contains a large amount of aromatic essential oil, so it smells good. The main ingredients include cnidilide, neocnidilide, ligustilide, and the like. The young shoots are eaten as a vegetable, and the rhizomes are dried and used as medicine. It has a mild medicinal property and a sour taste, and when it enters the body, it has an analgesic effect that stimulates blood circulation and relieves pain. Therefore, it is often applied to headaches. For women, it eliminates menstrual irregularities, menstrual pain, postpartum abdominal pain and dizziness. In addition, it activates the function of the liver, and when it is taken for anemia, it is effective for hematopoiesis. It is also improving symptoms of pain in the heart area due to insufficiency of contractility of the heart muscle. Those with weak back and leg bones and frequent muscle cramps can take this symptom and improve it.
당귀(Angelica gigas)는 쓴맛과 단맛 또는 매운 맛이 나는 식물 뿌리로서, 주요 성분으로 데커신(Decursin), 데커시놀(Decursinol), 노다케닌(Nodakenin) 등의 쿠마린(Coumarin) 유도체, 알파-피넨(α―Pinene), 리모넨(Limonene), 베타-에우데스몰(β―Eudesmol), 엘레몰(Elemol), 임페라토린(Imperatorin) 등이 있다. 각종 여성 질환, 생리불순, 생리통, 빈혈, 자궁 발육 부진, 산후 혈액 부족, 갱년기 장애 등에 두루 효과가 있고 여성 호르몬 분비를 원활하게 도와주는 작용이 있으며 해독작용을 증진시키는 효과가 있다. Angelica gigas is a plant root that has a bitter, sweet or spicy taste, and its main ingredients are coumarin derivatives such as decursin, decursinol, and nodakenin, alpha-pinene. (α-Pinene), limonene (Limonene), beta-eudesmol (β-Eudesmol), elemol (Elemol), imperatorin (Imperatorin) and the like. It is effective for various female diseases, menstrual irregularity, menstrual pain, anemia, underdevelopment of the uterus, lack of blood after childbirth, and menopausal disorders.
황기(Astragalus membranaceus)는 주로 이뇨, 강장, 혈압강하, 혈당강하, 면역증강, 항종양, 항바이러스 등의 목적으로 사용되며 황기에 존재하는 생리활성 물질로는 이소플라본 배당체 중의 하나인 포르모노네틴(formononetin)과 트리페노이드 글리코사이드(triterpenoide glycoside) 및 베타시토스테롤(β-sitosterol) 등의 물질과 사포닌류로써 아스트라갈로사이드(astragaloside)류 및 당이 주성분으로 알려져 있다. Astragalus membranaceus is mainly used for diuresis, tonicity, blood pressure lowering, blood sugar lowering, immunity enhancement, antitumor, antiviral, etc. Substances such as formononetin), triterpenoide glycoside, and beta-sitosterol, as well as saponins, astragaloside and sugar are known as main components.
인삼, 홍삼 또는 흑삼의 효능증강과 관련한 선행기술을 예로 들면, 국내 등록특허공보 등록번호 10-0425022호에는 오미자, 산사자, 산수유, 모과, 매실, 유자, 탱자, 사과, 석류 및 오렌지 중에서 선택된 1종 또는 2종 이상의 생약재를 인삼과 함께 증숙함으로써 진세노사이드 (Rg3+Rg5)/(Rb1+Rb2+Rc+Rd) 비율이 증강된 가공인삼 추출물에 대해 개시하고 있으나, 상기 특허는 진세노사이드 Rg3와 Rg5의 함량 증가가 확인되었고, 혈관이완작용이 증강되었다는 기재만 있을 뿐이다.For example, in the prior art related to the enhancement of the efficacy of ginseng, red ginseng or black ginseng, Korean Patent Publication No. 10-0425022 discloses one selected from omija, hawthorn, cornflower, quince, plum, citron, tangja, apple, pomegranate and orange. Or, a ginsenoside (Rg3+Rg5)/(Rb1+Rb2+Rc+Rd) ratio is enhanced by steaming two or more kinds of herbal medicines with ginseng, but the patent discloses a processed ginseng extract with enhanced ginsenoside Rg3 and An increase in the content of Rg5 was confirmed, and there is only a description that the vasodilatory action was enhanced.
또한 국내 등록특허공보 등록번호 10-1343819호에는 홍삼에 함유된 다양한 종류의 진세노사이드에 대한 효능을 이용하면서 비타민 및 미네랄과 조합한 홍삼농축액 조성물에 대해 개시하고 있으나, 상기 특허는 효모균을 이용한 발효과정 없이 홍삼농축액 분말에 비타민 및 미네랄을 단순 첨가하고 있다는 점에서 본 발명의 제조방법과 차이가 있다.In addition, Korean Patent Publication No. 10-1343819 discloses a red ginseng concentrate composition in combination with vitamins and minerals while using the efficacy of various types of ginsenosides contained in red ginseng, but the patent is a fermentation using yeast bacteria. It is different from the manufacturing method of the present invention in that vitamins and minerals are simply added to the red ginseng concentrate powder without a process.
또한 국내 등록특허공보 등록번호 10-1667284호에는 흑삼 및 혼합 생약의 발효추출물을 유효성분으로 함유하는 화장료 조성물에 대해 개시하고 있다. 그러나, 상기 특허는 별다른 첨가물 투입없이 흑삼, 구기자, 당귀, 오가피 및 복분자의 추출물을 버섯균사체로 발효시켜 조성물을 얻고 있어 다단계의 효모발효과정을 거치는 본 발명의 제조방법과 차이가 있다.In addition, Korean Patent Registration No. 10-1667284 discloses a cosmetic composition containing a fermented extract of black ginseng and mixed herbal medicine as an active ingredient. However, the above patent is different from the manufacturing method of the present invention, which undergoes a multi-step yeast fermentation process, since extracts of black ginseng, goji berry, angelica, sorghum and bokbunja are fermented with mushroom mycelium without any additional additives.
본 발명자들은 흑삼에 없는 미네랄, 유효한 생리활성 성분을 보강하고 흑삼중에 존재하는 특정 진세노사이드 함량을 강화시키려는 목적으로 수 년간 연구끝에 백복령, 감초, 숙지황, 백작약 및 육계의 혼합생약을 선택하고 이들 혼합생약을 미네랄이 함유된 효모균으로 발효한 다음 여기에 흑삼을 넣어 추가 발효 및 증숙과정을 거쳐 본 발명의 목적을 완성하였다.After several years of research for the purpose of reinforcing minerals and effective physiologically active ingredients not found in black ginseng, and enhancing the specific ginsenoside content in black ginseng, the present inventors selected a mixed herbal medicine of baekbokryeong, licorice, sukjihwang, white peony and broiler, and mixed these After fermenting the herbal medicine with yeast bacteria containing minerals, black ginseng was added thereto and subjected to additional fermentation and steaming processes to complete the object of the present invention.
본 발명의 목적은 생약재 미네랄 효모 발효액을 이용하여 제조되는 발효 흑삼 조성물의 제조방법을 제공하는 데 있다.It is an object of the present invention to provide a method for producing a fermented black ginseng composition prepared by using a herbal mineral yeast fermentation broth.
또한 본 발명의 다른 목적은 생약재 미네랄 효모 발효액을 이용하여 제조되는 발효 흑삼 조성물 및 이들의 다양한 용도를 제공하는 데 있다.In addition, another object of the present invention is to provide a fermented black ginseng composition prepared using a herbal mineral yeast fermentation broth and various uses thereof.
본 발명의 발효 흑삼 조성물 제조방법은,The method for producing the fermented black ginseng composition of the present invention,
세척한 생약재를 분쇄하고 살균하여 생약재 혼합물을 제조하는 단계(1단계);pulverizing and sterilizing the washed herbal materials to prepare a herbal mixture (step 1);
상기 생약재 혼합물의 전체중량에 대해 0.01~2중량%의 미네랄과 0.01~10중량% 효모균을 가하고 25~40℃에서 24~48시간 발효시켜 생약재 미네랄 효모 발효액을 제조하는 단계(2단계);Adding 0.01 to 2 wt% of minerals and 0.01 to 10 wt% yeast to the total weight of the herbal mixture, and fermenting at 25 to 40 °C for 24 to 48 hours to prepare a herbal mineral yeast fermentation broth (step 2);
제2단계의 생약재 미네랄 효모 발효액 100중량부에 5~100중량부의 흑삼을 침지하여 25~40℃에서 24~48시간 발효시키는 단계(3단계); immersing 5-100 parts by weight of black ginseng in 100 parts by weight of the herbal mineral yeast fermentation broth of the second step and fermenting it at 25-40 ℃ for 24-48 hours (step 3);
제3단계의 발효 혼합물을 75~80℃에서 6~8시간 증숙하는 단계(4단계);Steaming the fermentation mixture of the third step at 75-80° C. for 6-8 hours (step 4);
제4단계의 발효 혼합물을 맥반석과 황토가 있는 건조실에 넣고 25~40℃의 열풍을 부여하여 24~72시간 건조하는 단계(5단계); Putting the fermentation mixture of the fourth step in a drying room with elvan stone and loess and drying it for 24 to 72 hours by applying hot air at 25 to 40 ° C (step 5);
제5단계의 건조된 생약재와 흑삼의 혼합물을 탱크에 투입하고, 생약재와 흑삼의 중량대비 5∼20배의 주정 수용액을 투입하는 단계(6단계); 및Putting a mixture of the dried herbal medicine and black ginseng of the fifth step into the tank, and adding an aqueous solution of alcohol 5 to 20 times the weight of the herbal medicine and black ginseng (step 6); and
히터로 탱크를 가열하여 내부온도가 70∼95℃가 유지되도록 하고, 흑삼과 주정 수용액에 초음파진동과 미세 기포를 부여하여 추출한 다음 추출액을 분리 및 농축하여 발효 흑삼 조성물을 제조하는 단계(7단계);를 포함할 수 있다.Heating the tank with a heater so that the internal temperature is maintained at 70-95° C., applying ultrasonic vibration and fine bubbles to the aqueous solution of black ginseng and alcohol to extract it, and then separating and concentrating the extract to prepare a fermented black ginseng composition (Step 7) ; may be included.
상기 제1단계의 생약재는 백복령, 감초, 숙지황, 백작약 및 육계를 1~3 : 1~3 : 1~3 : 1~3 : 1~3의 중량비로 혼합하여 포함된다.The herbal medicine of the first step is included by mixing baekbokryeong, licorice, sukjihwang, ear pea and broiler in a weight ratio of 1-3: 1-3: 1-3: 1-3: 1-3.
또한 제1단계의 백복령, 감초, 숙지황, 백작약 및 육계의 생약재 혼합물에 선택적으로 인삼, 백출, 천궁, 당귀 및 황기 중에서 1종 이상을 1~3 중량비로 추가하여 혼합하여 본 발명의 효과를 더욱 증가 시킬 수 있다.In addition, the effect of the present invention is further increased by selectively adding and mixing one or more of ginseng, baekchul, cheongung, angelica and hwanggi in a weight ratio of 1 to 3 to the herbal medicine mixture of baekbokryeong, licorice, sukjihwang, peony and broiler in the first step. can do it
상기 제1단계의 생약재는 수조침지법과 로타리 분무세척 방법 등으로 세척하고 탈수 또는 건조할 수 있다. 또한 세척한 생약재는 분쇄기를 이용하여 120~180메쉬(mesh)의 크기로 각각 조분쇄 또는 파쇄할 수 있다. 또한 분쇄한 생약재는 살균탱크로 이송하여 90~120℃에서 30분~2시간 동안 증기살균하고, 상온으로 냉각한 후 배양기로 이송할 수 있다.The herbal material of the first step may be washed with a water bath immersion method and a rotary spray washing method, and then dehydrated or dried. In addition, the washed herbal material can be coarsely crushed or crushed, respectively, to a size of 120 to 180 mesh using a grinder. In addition, the crushed herbal material can be transferred to a sterilization tank, steam sterilized at 90-120° C. for 30 minutes to 2 hours, cooled to room temperature, and then transferred to an incubator.
상기 제2단계의 미네랄은 칼슘, 인, 칼륨, 철, 황, 염소, 나트륨, 구리, 아연, 망간, 마그네슘, 셀레늄, 요오드, 몰리브덴, 코발트, 크롬으로 이루어진 그룹 중 하나 이상의 공급원으로 이루어질 수 있으며, 바람직하게는 칼슘, 철, 구리, 아연, 망간, 마그네슘 및 셀레늄의 공급원으로 이루어질 수 있다.The mineral of the second step may consist of one or more sources from the group consisting of calcium, phosphorus, potassium, iron, sulfur, chlorine, sodium, copper, zinc, manganese, magnesium, selenium, iodine, molybdenum, cobalt, and chromium, Preferably, it may consist of a source of calcium, iron, copper, zinc, manganese, magnesium and selenium.
더 나아가, 상기 제2단계의 바람직한 미네랄인 칼슘, 철, 구리, 아연, 망간, 마그네슘 및 셀레늄의 공급원으로 수용성해조칼슘, 젖산철, 황산동, 황산아연, 황산망간, 황산마그네슘, 아셀렌산나트륨을 조성하는 것으로 이루어진다.Furthermore, water-soluble seaweed calcium, iron lactate, copper sulfate, zinc sulfate, manganese sulfate, magnesium sulfate, and sodium selenite are used as sources of calcium, iron, copper, zinc, manganese, magnesium and selenium, which are preferred minerals in the second step. It consists of creating
상기 제2단계의 효모균은 사카로마이세스 세레비지에(Saccharomyces cerevisiae), 사카로마이세스 엘리소이더스(Saccharomyces ellipsoidus)를 포함하는 그룹에서 선택되는 것 중에 적어도 하나일 수 있으며 통상적인 효모균을 이용하는 발효조건에서 발효를 시킨다.The yeast of the second step may be at least one selected from the group including Saccharomyces cerevisiae , Saccharomyces ellipsoidus, and fermentation using conventional yeast fermented under conditions.
상기 제6단계의 주정 수용액은 50~95중량% 주정이 바람직하며, 더 바람직하게는 60~80중량% 주정이다.The aqueous solution of alcohol in the sixth step is preferably 50 to 95% by weight of alcohol, and more preferably 60 to 80% by weight of alcohol.
상기 제7단계의 생약재와 흑삼 혼합물은 직물 주머니에 넣고 용수에 투입하여 추출작업 후 찌꺼기의 분리가 용이하게 이루어지도록 하였다.The herbal medicine and black ginseng mixture of the seventh step was put in a fabric bag and put into water to facilitate the separation of the residue after the extraction operation.
상기에 기술된 방법으로 본 발명은 발효 흑삼 조성물 및 발효 흑삼 조성물을 포함하는 건강기능식품, 영양보충용식품, 기능성식품, 건강식품, 다류식품과 같은 여러 식품을 제공한다.By the method described above, the present invention provides a fermented black ginseng composition and various foods such as health functional food, nutritional supplement food, functional food, health food, and tea food containing the fermented black ginseng composition.
본 발명의 제조방법에 의하면 다양한 생약재의 혼합물에 미네랄을 첨가하고 효모를 이용하여 발효함으로써, 효모를 단독 접종하여 발효한 경우에 비해 생약재와 흑삼을 효과적으로 발효시킬 수 있으며, 이런 발효로 인해 생약재와 흑삼에 함유되어 있던 생리활성물질의 유효성분을 식품으로 효과적으로 이용할 수 있다. 또한 상기 생약재 미네랄 효모 발효액에 흑삼을 침지해 발효시킴으로써 각종 미네랄 성분이 다량 함유될 수 있고 상기 생약의 유효성분들이 흑삼 내에 함유된다. According to the manufacturing method of the present invention, by adding minerals to a mixture of various herbal medicines and fermenting them using yeast, herbal medicines and black ginseng can be fermented more effectively than when fermented by inoculating yeast alone. The active ingredients of the physiologically active substances contained in it can be effectively used as food. In addition, by immersing and fermenting black ginseng in the herbal mineral yeast fermentation broth, a large amount of various mineral components can be contained, and the active ingredients of the herbal medicine are contained in the black ginseng.
뿐만 아니라, 건조발효 과정을 거치면서 흑삼의 건조된 표면이 차폐막의 역할을 하여 유용한 휘발성분의 휘발을 상당부분 막을 수 있게 되며 흑삼 내의 생리활성이 강한 특정 진세노사이드 성분들의 함량이 증가하는 효과를 얻을 수 있다. 특히 진세노사이드 Rg2, Rd, F4, Rg3, Rk1, Rg5 함량이 일반 발효과정을 거친 흑삼에 비하여 현저히 증가하였다.In addition, during the dry fermentation process, the dried surface of black ginseng acts as a shielding film, thereby preventing the volatilization of useful volatile components to a large extent and increasing the content of specific ginsenoside components with strong physiological activity in black ginseng. can be obtained In particular, the contents of ginsenosides Rg2, Rd, F4, Rg3, Rk1, and Rg5 were significantly increased compared to that of black ginseng subjected to general fermentation.
본 발명의 방법으로 제조된 발효 흑삼에서 증가된 진세노사이드의 주요 약리작용은 다음 표 2와 같다.The main pharmacological actions of ginsenosides increased in fermented black ginseng prepared by the method of the present invention are shown in Table 2 below.
또한, 본 발명의 생약재 미네랄 효모 발효액을 이용해 제조된 발효 흑삼 조성물은 흑삼 특유의 강한 향이 약화되는 대신 한약재의 특유의 맛과 향이 가해짐으로써 소비자들이 거부감 없이 섭취할 수 있다.In addition, the fermented black ginseng composition prepared using the herbal mineral yeast fermented liquid of the present invention can be consumed without objection by consumers by adding the unique taste and flavor of herbal medicines instead of weakening the strong flavor of black ginseng.
본 발명에서 제조된 발효 흑삼 조성물은 일반 흑삼과 마찬가지로 섭취량에 특별한 제한이 없고, 독성을 나타내지 않는다.The fermented black ginseng composition prepared in the present invention has no particular limitation on intake, and does not exhibit toxicity, like general black ginseng.
따라서, 본 발명은 발효 흑삼 조성물을 식품 조성물의 형태로 제공할 수 있으며, 식품조성물로는 영양보충식품, 건강식품 등의 형태가 될 수 있다. 또한 본 발명의 발효 흑삼 조성물을 식품에 첨가함으로써, 흑삼의 유효성분을 용이하게 섭취할 수 있으며, 식품의 맛과 향을 풍부하게 하며 소화 흡수를 용이하게 할 수 있다.Therefore, the present invention may provide the fermented black ginseng composition in the form of a food composition, and the food composition may be in the form of a nutritional supplement, health food, or the like. In addition, by adding the fermented black ginseng composition of the present invention to food, it is possible to easily ingest the active ingredient of black ginseng, enrich the taste and flavor of food, and facilitate digestion and absorption.
도 1은 본 발명의 생약재 미네랄 효모 발효액을 이용하여 제조되는 발효 흑삼 조성물 제조 과정을 순차적으로 나타내는 흐름도이다.1 is a flow chart sequentially showing the manufacturing process of a fermented black ginseng composition prepared by using the herbal mineral yeast fermentation broth of the present invention.
이하 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 그러나 본 발명은 여기서 설명되는 실시예에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 내용이 철저하고 완전해지고, 당업자에게 본 발명의 사상을 충분히 전달하기 위해 제공하는 것이다.Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, it is provided so that this disclosure will be thorough and complete, and will fully convey the spirit of the invention to those skilled in the art.
<실시예 1. 생약재 미네랄 효모 발효액을 이용한 발효 흑삼 조성물의 제조><Example 1. Preparation of fermented black ginseng composition using herbal mineral yeast fermentation broth>
세척한 백복령, 감초, 숙지황, 백작약, 및 육계를 1 : 1 : 1 : 1 : 1의 중량비로 혼합한 다음, 분쇄기를 이용하여 120~180메쉬(mesh)의 크기로 각각 조분쇄 또는 파쇄하여 생약재 혼합물을 제조한다. 그다음 살균탱크로 이송하여 90~120℃에서 30분~2시간 동안 증기살균하고, 상온으로 냉각한 후 배양기로 이송한다.After mixing the washed baekbokryeong, licorice, succulent yellow, white peony, and broiler in a weight ratio of 1: 1: 1: 1: 1, use a grinder to coarsely pulverize or crush each into a size of 120 to 180 mesh to make herbal medicines Prepare the mixture. Then, it is transferred to a sterilization tank, steam sterilized at 90~120°C for 30 minutes to 2 hours, cooled to room temperature, and then transferred to an incubator.
상기 생약재 혼합물의 1kg에 대해 10g의 미네랄(칼슘, 철, 구리, 아연, 망간, 마그네슘 및 셀레늄 공급원으로서의 수용성해조칼슘(칼슘 12.1% 함유), 젖산철, 황산동, 황산아연, 황산망간, 황산마그네슘, 아셀렌산나트륨)을 미네랄 기준 같은 당량비로 첨가해주었다. 또한 50g의 사카로마이세스 세레비지에(Saccharomyces cerevisiae) 효모균을 가하고 균질하게 혼합한 다음 37℃의 배양조건에서 36시간 발효시켜 생약재 미네랄 효모 발효액을 제조한다. 10 g of minerals (calcium, iron, copper, zinc, manganese, magnesium and selenium as a source of water-soluble seaweed calcium (containing 12.1% of calcium), iron lactate, copper sulfate, zinc sulfate, manganese sulfate, magnesium sulfate, Sodium selenite) was added in the same equivalence ratio based on the mineral. In addition, 50 g of Saccharomyces cerevisiae yeast is added and mixed homogeneously, and then fermented for 36 hours at 37° C. to prepare a fermented herbal mineral yeast.
흑삼 200g(상업적 구매)을 상기 제조된 생약재 미네랄 효모 발효액에 침지하여 37℃의 배양조건에서 36시간 발효시킨다음 75℃에서 7시간 증숙시킨다.200 g of black ginseng (commercially purchased) is immersed in the prepared herbal medicinal mineral yeast fermentation broth, fermented for 36 hours at 37° C., and then steamed at 75° C. for 7 hours.
발효 및 증숙된 생약재 흑삼 발효 혼합물을 맥반석과 황토가 있는 건조실에 넣고 40℃의 열풍을 부여하여 48시간 동안 건조한다.The fermented and steamed herbal black ginseng fermentation mixture is placed in a drying room with elvan stone and loess, and is dried for 48 hours by applying hot air at 40°C.
건조된 생약재와 흑삼의 혼합물을 탱크에 투입하고, 70중량% 주정 10L를 투입한다.A mixture of dried herbal medicine and black ginseng is put into the tank, and 10L of 70 wt% alcohol is added.
히터로 탱크를 가열하여 내부온도가 80∼85℃가 유지되도록 하고, 생약재와 흑삼의 혼합물과 주정 수용액에 초음파진동과 미세 기포를 부여하여 8시간 추출 및 분리 농축하여 발효 흑삼 조성물 약 150g을 제조하였다.The tank was heated with a heater so that the internal temperature was maintained at 80-85° C., and ultrasonic vibration and microbubbles were applied to the mixture of herbal medicines and black ginseng and the aqueous alcohol solution, extracted and concentrated for 8 hours to prepare about 150 g of a fermented black ginseng composition. .
<비교예 1. 생약재 미네랄 효모 발효액을 이용한 발효 흑삼 조성물의 제조><Comparative Example 1. Preparation of fermented black ginseng composition using fermented herbal medicinal mineral yeast>
실시예 1과 동일하게 실시하되, 미네랄(칼슘, 철, 구리, 아연, 망간, 마그네슘 및 셀레늄 공급원) 혼합발효 없이 50g의 사카로마이세스 세레비지에(Saccharomyces cerevisiae) 효모균을 이용한 생약재 효모 발효액을 이용한 가공 생약재 흑삼 조성물을 제조하였다.The same procedure as in Example 1, but without mixing minerals (calcium, iron, copper, zinc, manganese, magnesium and selenium source) 50 g of Saccharomyces cerevisiae using yeast fermented herbal medicine yeast A processed herbal medicine black ginseng composition was prepared.
<실시예 2. 본 발명의 발효 흑삼 조성물의 진세노사이드와 미네랄 함량 분석><Example 2. Analysis of ginsenoside and mineral content of fermented black ginseng composition of the present invention>
진세노사이드의 함량분석은, 당 분야에서 통상적으로 사용하는 HPLC 분석방법으로 아래와 같은 분석조건으로 확인하였다.Analysis of the content of ginsenosides was confirmed under the following analysis conditions by HPLC analysis methods commonly used in the art.
미네랄의 함량분석은, 유도결합플라즈마질량분석기(ICP/MS :Varian820.Australia)를 이용해 분석하였다. 시료의 간섭물질의 방해 영향을 최적화 하기 위하여 CRI(collision reaction interface) 시스템을 적용하여 분석하였으며 아래와 같은 분석조건으로 확인하였다.The mineral content was analyzed using an inductively coupled plasma mass spectrometer (ICP/MS: Varian820.Australia). In order to optimize the interference effect of the interfering material in the sample, the CRI (collision reaction interface) system was applied and analyzed, and the analysis conditions were confirmed as follows.
본발명의 제조한 발효 흑삼 조성물의 효모발효 또는 미네랄 효모발효에 따른 진세노사이드와 미네랄의 함량을 분석하여 그 결과는 하기 표 3과 표 4에 나타내었다.The contents of ginsenosides and minerals according to yeast fermentation or mineral yeast fermentation of the fermented black ginseng composition prepared according to the present invention were analyzed, and the results are shown in Tables 3 and 4 below.
표 3의 진세노사이드 함량분석 결과에서 보듯이, 본 발명 실시예 1의 미네랄 효모발효를 이용한 발효 흑삼 조성물은 비교예 1의 미네랄 없이 효모발효를 이용한 발효 흑삼 조성물보다 5배 이상의 Rg2, Rd, F4 진세노사이드 함량이 증가되어 Rg2, Rd, F4 진세노사이드의 생리활성(혈소판응집 억제작용, 프라스민 활성화 작용, 미백효과, 면역조절 보조)이 더욱 강화된 우수한 발효 흑삼 조성물을 얻었다.As shown in the ginsenoside content analysis results in Table 3, the fermented black ginseng composition using the mineral yeast fermentation of Example 1 of the present invention has Rg2, Rd, F4 5 times more than the fermented black ginseng composition using the yeast fermentation without the mineral of Comparative Example 1. An excellent fermented black ginseng composition was obtained in which the physiological activities of Rg2, Rd, and F4 ginsenosides (platelet aggregation inhibitory action, plasmin activation action, whitening effect, immunomodulatory aid) were further enhanced due to the increased ginsenoside content.
표 4의 미네랄 함량분석 결과에서, 본 발명 실시예 1의 미네랄 효모발효를 이용한 발효 흑삼 조성물은 비교예 1의 미네랄 없이 단지 효모발효를 이용한 발효 흑삼 조성물보다 미네랄이 강화된 우수한 발효 흑삼 조성물을 얻었다.From the mineral content analysis results in Table 4, the fermented black ginseng composition using mineral yeast fermentation of Example 1 of the present invention obtained an excellent fermented black ginseng composition with enhanced minerals than the fermented black ginseng composition using only yeast fermentation without the minerals of Comparative Example 1.
상기 표 3 및 표 4에서 알 수 있듯이, 본 발명의 다양한 생약재의 혼합물에 미네랄을 첨가하고 효모를 이용하여 발효함으로써, 효모를 단독 접종하여 발효한 경우에 비해 생약재와 흑삼에 함유되어 있던 특정 진세노사이드 생리활성물질의 유효성분이 강화된 식품으로 효과적으로 이용할 수 있다. 또한 상기 생약재 미네랄 효모 발효액에 흑삼을 침지해 발효시킴으로써 각종 미네랄 성분이 다량 함유될 수 있고 상기 생약의 유효성분들이 흑삼 내에 함유될 수 있다. As can be seen from Tables 3 and 4 above, by adding minerals to the mixture of various herbal medicines of the present invention and fermentation using yeast, the specific ginseno contained in herbal medicines and black ginseng was compared to the case of fermentation by inoculating yeast alone. It can be effectively used as a food fortified with active ingredients of side bioactive substances. In addition, by immersing and fermenting black ginseng in the herbal mineral yeast fermentation broth, a large amount of various mineral components may be contained, and the active ingredients of the herbal medicine may be contained in the black ginseng.
뿐만 아니라, 추가의 특별한 건조 과정을 거치면서 흑삼의 건조된 표면이 차폐막의 역할을 하여 유용한 휘발성분의 휘발을 상당부분 막을 수 있게 되며 흑삼 내의 생리활성이 강한 특정 진세노사이드 성분들의 함량이 증가하는 효과를 얻을 수 있다. 특히 진세노사이드 Rg2, Rd, F4 함량이 일반 발효과정을 거친 흑삼에 비하여 현저히 증가하였으며, 아울러 7종의 미네랄 중에서도 특히 구리, 아연 및 망간 성분이 현저하게 증가하는 것으로 나타났다.In addition, through an additional special drying process, the dried surface of black ginseng acts as a shielding film to prevent volatilization of useful volatile components to a large extent, and the content of specific ginsenoside components with strong physiological activity in black ginseng increases. effect can be obtained. In particular, the contents of ginsenosides Rg2, Rd, and F4 were significantly increased compared to that of black ginseng subjected to general fermentation, and copper, zinc and manganese components among the 7 minerals were significantly increased.
이를 통해 본 발명의 제조공정에서 미네랄을 첨가 여부에 따라 조성물의 영양성분이 달라지며, 결과적으로 미네랄을 첨가하여 효모발효를 진행시킴으로써 진세노사이드와 미네랄 모두 영양학적으로 풍부한 발효 흑삼 조성물을 얻을 수 있었다.Through this, the nutritional component of the composition changes depending on whether or not minerals are added in the manufacturing process of the present invention. .
<실험예 1. 발효 흑삼 조성물의 혈소판 응집 저해 활성><Experimental Example 1. Platelet aggregation inhibitory activity of fermented black ginseng composition>
혈소판은 인간 농축 혈소판을 사용하였으며, 이를 washing buffer(138mM NaCl, 2.7mM KCl, 12mM NaHCO3, 0.36mM NaH2PO4, 5.5mM Glucose, 1mM EDTA, pH 6.5)로 1회 세척하였다. 이후, suspending buffer(138mM NaCl, 2.7mM KCl, 12mM NaHCO3, 0.36mM NaH2PO4, 5.5mM Glucose, 0.49mM MgCl2, 0.25% gelatin, pH 7.4)에 재현탁한 후, 3,000rpm에서 10분간 원심분리한 후 다시 suspending buffer에 재현탁하였으며, 이때 혈소판 수는 4x109/ml이 되도록 조정하였다. 이후 1ml 현탁액에 2.5μl 콜라겐을 가해 5분간 반응시키고, whole-blood aggregometer(Chrono-log, USA)를 사용하여 37℃에서 혈소판 응집을 측정하였다.Platelets were human concentrated platelets, which were washed once with washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 5.5 mM Glucose, 1 mM EDTA, pH 6.5). Then, resuspended in suspending buffer (138mM NaCl, 2.7mM KCl, 12mM NaHCO 3 , 0.36mM NaH 2 PO 4 , 5.5mM Glucose, 0.49mM MgCl 2 , 0.25% gelatin, pH 7.4), and centrifuged at 3,000 rpm for 10 minutes. After separation, it was resuspended in suspending buffer, and the platelet count was adjusted to be 4x10 9 /ml. Then, 2.5 μl collagen was added to 1 ml suspension and reacted for 5 minutes, and platelet aggregation was measured at 37° C. using a whole-blood aggregometer (Chrono-log, USA).
실시예 1의 발효 흑삼 조성물과 비교예 1의 인간 혈소판 응집 저해 활성을 평가하여 그 결과를 표 5에 나타내었다.The fermented black ginseng composition of Example 1 and the human platelet aggregation inhibitory activity of Comparative Example 1 were evaluated, and the results are shown in Table 5.
표 5에 나타낸 바와 같이, 먼저 아스피린은 0.5mg/ml 농도에서, 37.6%의 농도 의존적으로 강력한 혈소판 응집 저해를 나타내어 임상에서 항혈전제로 사용되는 근거를 알 수 있었다. 반면, 실시예 1의 발효 흑삼 조성물은 5mg/ml 농도에서 인간 혈소판 응집능 41.2%를 보였으며, 이는 비교예 1의 5mg/ml 농도에서 인간 혈소판 응집능 60.7%와 비교하면 상당히 우수한 혈소판 응집 저해 활성을 가짐을 알 수 있다. 따라서, 본 발명의 발효 흑삼 조성물은 우수한 혈소판 응집 저해 활성을 나타냄을 확인하였다.As shown in Table 5, first, aspirin showed strong inhibition of platelet aggregation in a concentration-dependent manner of 37.6% at a concentration of 0.5 mg/ml, thereby confirming the evidence for its use as an antithrombotic agent in clinical practice. On the other hand, the fermented black ginseng composition of Example 1 showed 41.2% human platelet aggregation ability at a concentration of 5 mg/ml, which was significantly superior to platelet aggregation inhibitory activity at a concentration of 5 mg/ml of Comparative Example 1 of 60.7% can be seen to have Therefore, it was confirmed that the fermented black ginseng composition of the present invention exhibits excellent platelet aggregation inhibitory activity.
<실험예 2. 생약재 발효 미네랄 발효 흑삼 조성물의 면역력 증가 활성><Experimental Example 2. Immunity-increasing activity of herbal fermented mineral fermented black ginseng composition>
2-1. 림프구 증식 활성에 대한 실험2-1. Experiments on lymphocyte proliferative activity
5주령의 Balb/c 마우스로부터 비장을 적출하고, 비장세포(splenocytes)의 수가 2×105/100㎕의 밀도로 조정하여 각 웰(well)에 넣고 본 발명에 따른 조성물을 각각 10㎎/㎖, 1㎎/㎖, 및 0.1㎎/㎖를 첨가하였다.A spleen was removed from a 5-week-old Balb/c mouse, the number of splenocytes was adjusted to a density of 2×10 5 /100 μl, and the composition according to the present invention was added to each well at 10 mg/ml. , 1 mg/ml, and 0.1 mg/ml were added.
양성 대조군으로 T-세포 및 B-세포의 유사분열 물질인 콘카바날린-A(Concavanallin-A;이하 Con-A라 약칭함)와 지질 다당류(Lipopolysaccharide;이하 LPS라 약칭함)의 최종농도가 각각 0.5㎍/㎖ 및 5㎍/㎖가 되도록 조정하여 각 웰(well)에 처리하고, 실험군과 대조군을 37℃, 5% CO2 조건 하에서 3일간 배양하고 시료에 의한 림프구의 증식활성을 조사하였다.As a positive control, the final concentrations of Concavanalin-A (hereinafter abbreviated as Con-A) and lipopolysaccharide (hereinafter abbreviated as LPS), which are mitotic substances of T-cells and B-cells, were respectively It was adjusted to be 0.5 μg/ml and 5 μg/ml and treated in each well, and the experimental group and the control group were cultured for 3 days at 37° C. and 5% CO 2 conditions, and the proliferation activity of lymphocytes by the sample was investigated.
림프구의 증식활성은 MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl- tetrazolium bromide]법으로 수행하였으며, 상기 MTT법은 5㎎/㎖의 농도로 조정된 MTT시약을 각 웰(well)에 50㎕첨가하고 6시간 배양하여 MTT시약과 살아있는 세포가 생산하는 미토콘드리아 탈수소효소(mitochondria dehydrogense)와 반응하여 생성된 비수용성의 진청색 포마잔(formazan)의 양을 570㎚에서 흡광도를 측정함으로써 림프구의 증식활성을 측정하였다.The proliferative activity of lymphocytes was performed by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] method, and the MTT method was performed with the MTT reagent adjusted to a concentration of 5 mg/ml. was added to each well, incubated for 6 hours, and the amount of insoluble dark blue formazan produced by reacting with MTT reagent and mitochondria dehydrogenase produced by living cells was measured at 570 nm. By measuring the absorbance, the proliferative activity of lymphocytes was measured.
본 실험예의 결과는 표 6에 나타낸 바와 같이 본 발명에 따른 조성물이 시료 무처리 대조군에 비하여 높은 비장세포의 증식활성을 나타내었으며 비특이적으로 비장세포를 직접 자극하는 활성작용이 있음을 확인하였다.As shown in Table 6, the results of this Experimental Example confirmed that the composition according to the present invention exhibited a higher proliferative activity of splenocytes compared to the sample untreated control group, and had an activity of non-specifically stimulating splenocytes directly.
2-2. 사이토카인 유도에 대한 실험2-2. Experiments on cytokine induction
5주령의 Balb/c 마우스로부터 비장을 적출하고, 비장세포(splenocytes)의 수를 2×106/500㎕의 밀도로 조정하여 각 웰(well)에 넣고 본 발명의 조성물을 각각 10㎎/㎖, 1㎎/㎖, 0.1㎎/㎖를 첨가하여 24시간 동안 동시배양 하였다.The spleen was removed from a 5-week-old Balb/c mouse, the number of splenocytes was adjusted to a density of 2×10 6 /500 μl, and put into each well, and the composition of the present invention was added to each well at 10 mg/ml. , 1 mg/ml, and 0.1 mg/ml were added and co-cultured for 24 hours.
또한, 양성 대조군으로 Con-A의 최종농도를 0.5㎍/㎖가 되도록 조정하여 웰(well)에 처리하고 24시간 동안 배양하였고, 배양완료 후에 상등액만을 회수하고 상등액에 유도 분비된 여러 가지 사이토카인 (IL-2, IL-4 및 IL-10)을 각 사이토카인 킷(cytokine kit)을 이용하여 측정하였다.In addition, as a positive control, the final concentration of Con-A was adjusted to 0.5 μg/ml, treated in wells, and cultured for 24 hours. IL-2, IL-4 and IL-10) were measured using each cytokine kit.
본 시험의 결과는 표 7에 나타낸 바와 같이 마우스의 췌장 세포를 직접 활성화시켜 IL-2, IL-4 및 IL10의 면역 관련 사이토카인을 유도하는 면역자극효과가 있음을 확인하였다.As shown in Table 7, the results of this test confirmed that there was an immunostimulatory effect inducing the immune-related cytokines of IL-2, IL-4 and IL10 by directly activating the pancreatic cells of the mouse.
본 발명은 사이토카인의 종류, 조성물액의 농도에 따라 사이토카인을 유도하는 정도가 달랐으나, 농도의존적으로 사이토카인 유도체(cytokine inducer)로의 활성이 있음을 확인하였다.In the present invention, the degree of cytokine induction was different depending on the type of cytokine and the concentration of the composition solution, but it was confirmed that there was activity as a cytokine inducer in a concentration-dependent manner.
본 발명에서 제조된 발효 흑삼 조성물은 일반 흑삼과 마찬가지로 섭취량에 특별한 제한이 없고, 독성을 나타내지 않는다.The fermented black ginseng composition prepared in the present invention has no particular limitation on intake, and does not exhibit toxicity, like general black ginseng.
또한, 본 발명의 생약재 미네랄 효모 발효액을 이용한 발효 흑삼 조성물은 흑삼 특유의 강한 향이 약화되는 대신 한약재의 특유의 맛과 향이 가해짐으로써 소비자들이 거부감 없이 섭취할 수 있다.In addition, the fermented black ginseng composition using the herbal mineral yeast fermented liquid of the present invention can be consumed without objection by consumers by adding the unique taste and flavor of herbal medicines instead of weakening the strong aroma of black ginseng.
따라서, 본 발명은 발효 흑삼 조성물을 식품 조성물의 형태로 제공할 수 있으며, 식품조성물로는 영양보충식품, 건강식품 등의 형태가 될 수 있다. 본 발명의 발효 흑삼 조성물을 식품에 첨가함으로써, 흑삼의 유효성분을 용이하게 섭취할 수 있으며, 식품의 맛과 향을 풍부하게 하며 소화 흡수를 용이하게 할 수 있다.Therefore, the present invention may provide the fermented black ginseng composition in the form of a food composition, and the food composition may be in the form of a nutritional supplement, health food, or the like. By adding the fermented black ginseng composition of the present invention to food, it is possible to easily ingest the active ingredients of black ginseng, enrich the taste and flavor of food, and facilitate digestion and absorption.
<제제예 1. 발효 흑삼 조성물 함유 건강식품의 제조><Formulation Example 1. Preparation of health food containing fermented black ginseng composition>
1-1. 건강식품의 제조1-1. Manufacturing of health food
실시예 1에서 제조된 발효 흑삼 조성물 41kg, 맥주효모 20kg, 분리대두단백 18.4kg, 폴리덱스트로스 10kg, 난소화성덱스트린 8kg, 비타민B1염산염 0.2kg, 비타민B2 0.1kg, 비타민B6염산염 0.1kg, 비타민C 0.5kg, 비타민E 0.5kg, 해조칼슘 1kg, 산화아연 0.2kg을 혼합 및 가공하여 건강식품을 제조하였다.The fermented black ginseng composition prepared in Example 1 41 kg, brewer's yeast 20 kg, soy protein isolate 18.4 kg, polydextrose 10 kg, indigestible dextrin 8 kg, vitamin B1 hydrochloride 0.2 kg, vitamin B2 0.1 kg, vitamin B6 hydrochloride 0.1 kg, vitamin C 0.5 kg , 0.5 kg of vitamin E, 1 kg of seaweed calcium, and 0.2 kg of zinc oxide were mixed and processed to prepare a health food.
1-2. 기능성식품의 제조1-2. Manufacturing of functional foods
실시예 1에서 제조된 발효 흑삼 조성물 81kg, 코엔자임큐텐 1kg, 포도씨추출물분말 2kg, 비타민C 2kg, 비타민E 2kg, 에리스리톨 10kg, 사과산 2kg을 혼합 및 가공하여 기능성식품을 제조하였다.Functional food was prepared by mixing and processing 81 kg of the fermented black ginseng composition prepared in Example 1, 1 kg of coenzyme Q10, 2 kg of grape seed extract powder, 2 kg of vitamin C, 2 kg of vitamin E, 10 kg of erythritol, and 2 kg of malic acid.
1-3. 영양보충용식품의 제조1-3. Manufacture of nutritional supplements
실시예 1에서 제조된 발효 흑삼 조성물 70kg, 분리대두단백 26.49kg, 해조칼슘 1kg, 산화마그네슘 0.75kg, 산화아연 0.02kg, 비타민 B1질산염 0.2kg, 염산피리독신 0.12kg, 니코틴산아미드 0.12kg, 비타민C 0.8kg, 비타민E 0.5kg을 혼합 및 가공하여 영양보충용식품을 제조하였다.70 kg of fermented black ginseng composition prepared in Example 1, 26.49 kg of soy protein isolate, 1 kg of seaweed calcium, 0.75 kg of magnesium oxide, 0.02 kg of zinc oxide, 0.2 kg of vitamin B1 nitrate, 0.12 kg of pyridoxine hydrochloride, 0.12 kg of nicotinic acid amide, 0.8 kg of vitamin C kg and 0.5 kg of vitamin E were mixed and processed to prepare a nutritional supplement.
1-4. 다류식품의 제조1-4. Manufacture of beverages
실시예 1에서 제조된 발효 흑삼 조성물 14kg, 마테추출물 12kg, 녹차추출물분말 10kg, 푸룬과즙분말 10kg, 이눌린 10kg, 에리스리톨 20kg, 유당 24kg을 혼합 및 가공하여 다류식품을 제조하였다.A tea food was prepared by mixing and processing 14 kg of the fermented black ginseng composition prepared in Example 1, 12 kg of mate extract, 10 kg of green tea extract powder, 10 kg of prune juice powder, 10 kg of inulin, 20 kg of erythritol, and 24 kg of lactose.
Claims (10)
상기 생약재 혼합물의 전체중량에 대해 0.01~2중량%의 미네랄과 0.01~10중량% 효모균을 가하고 발효시켜 생약재 미네랄 효모 발효액을 제조하는 단계(2단계);
상기 2단계의 생약재 미네랄 효모 발효액 100중량부 기준으로 5~100중량부의 흑삼을 침지하고 발효시키는 단계(3단계);
제3단계의 발효 혼합물을 증숙하는 단계(4단계);
제4단계의 발효 혼합물을 건조실에 넣고 열풍을 부여하여 건조시키는 단계(5단계);
제5단계의 건조된 생약재와 흑삼의 혼합물을 탱크에 투입하고, 주정 수용액을 투입하는 단계(6단계); 및
제6단계의 혼합액을 가열하면서 추출한 다음 추출액을 분리 및 농축하여 발효 흑삼 조성물을 제조하는 단계(7단계);
로 이루어진 것을 특징으로 하는 발효 흑삼 조성물의 제조방법.Pulverizing and sterilizing herbal medicines composed of baekbokryeong, licorice, sukjihwang, ear pea and broiler chicken to prepare a herbal mixture (step 1);
preparing a fermented herbal mineral yeast broth by adding and fermenting 0.01 to 2 wt% of minerals and 0.01 to 10 wt% yeast based on the total weight of the herbal mixture (step 2);
immersing and fermenting 5 to 100 parts by weight of black ginseng based on 100 parts by weight of the herbal mineral yeast fermentation broth of the second step (step 3);
steaming the fermentation mixture of the third step (step 4);
Putting the fermentation mixture of the fourth step in a drying chamber and drying it by applying hot air (step 5);
Putting the mixture of the dried herbal medicine and black ginseng of step 5 into the tank, and adding an aqueous alcohol solution (step 6); and
Preparing a fermented black ginseng composition by extracting the mixture while heating the sixth step, and then separating and concentrating the extract (step 7);
A method for producing a fermented black ginseng composition, characterized in that it consists of.
상기 1단계의 생약재는 백복령, 감초, 숙지황, 백작약 및 육계를 각각 1~3 : 1~3 : 1~3 : 1~3 : 1~3의 중량비로 혼합하는 것을 특징으로 하는 발효 흑삼 조성물의 제조방법.According to claim 1,
The herbal medicine of the first step is fermented black ginseng composition, characterized in that the fermented black ginseng composition is mixed in a weight ratio of 1-3: 1-3: 1-3: 1-3: 1-3, respectively. Way.
상기 1단계의 생약재는 인삼, 백출, 천궁, 당귀 및 황기로 이루어진 군 중에서 1종 이상을 각각 1~3 : 1~3 : 1~3 : 1~3 : 1~3의 중량비로 선택적으로 추가하여 혼합하는 것을 특징으로 하는 발효 흑삼 조성물의 제조방법.3. The method of claim 2,
The herbal medicine of step 1 is obtained by selectively adding at least one of ginseng, baekchul, cheongung, angelica and astragalus in a weight ratio of 1-3: 1-3: 1-3: 1-3: 1-3, respectively. Method for producing a fermented black ginseng composition, characterized in that mixing.
상기 제2단계의 미네랄은 칼슘, 인, 칼륨, 철, 황, 염소, 나트륨, 구리, 아연, 망간, 마그네슘, 셀레늄, 요오드, 몰리브덴, 코발트, 크롬 중에서 선택된 1종 이상의 미네랄인 것을 특징으로 하는 발효 흑삼 조성물의 제조방법.According to claim 1,
The mineral of the second step is calcium, phosphorus, potassium, iron, sulfur, chlorine, sodium, copper, zinc, manganese, magnesium, selenium, iodine, molybdenum, cobalt, fermentation, characterized in that at least one mineral selected from chromium A method for producing a black ginseng composition.
상기 제2단계의 효모균은 사카로마이세스 세레비지에(Saccharomyces cerevisiae), 사카로마이세스 엘리소이더스(Saccharomyces ellipsoidus) 중에서 선택된 1종 이상의 효모인 것을 특징으로 하는 발효 흑삼 조성물의 제조방법.According to claim 1,
The yeast of the second step is Saccharomyces cerevisiae ( Saccharomyces cerevisiae ), Saccharomyces ellipsoidus ( Saccharomyces ellipsoidus ) Method of producing a fermented black ginseng composition, characterized in that at least one yeast selected from the group consisting of.
상기 조성물은 진세노사이드 Rg2, Rd 및 F4 함량이 5배 이상 증가된 것을 특징으로 하는 발효 흑삼 조성물.7. The method of claim 6,
The composition is a fermented black ginseng composition, characterized in that the ginsenoside Rg2, Rd and F4 content is increased 5 times or more.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200059945A KR102436045B1 (en) | 2020-05-19 | 2020-05-19 | Fermented black ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200059945A KR102436045B1 (en) | 2020-05-19 | 2020-05-19 | Fermented black ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210143037A true KR20210143037A (en) | 2021-11-26 |
KR102436045B1 KR102436045B1 (en) | 2022-08-26 |
Family
ID=78700411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200059945A KR102436045B1 (en) | 2020-05-19 | 2020-05-19 | Fermented black ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102436045B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102490106B1 (en) * | 2022-09-13 | 2023-01-19 | 대동고려삼 주식회사 | Capsule product of red ginseng, Taekuksam, low temperature vacuum drying red ginseng using puffing and roasting and manufacturing process thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100425022B1 (en) | 2002-01-05 | 2004-03-27 | 롯데제과주식회사 | Ginseng extract and pharmaceutical composition containing it |
KR100864471B1 (en) * | 2007-04-25 | 2008-10-20 | 김재경 | A processed ginseng using extract of herb medicine and a producing method thereof |
KR101343819B1 (en) | 2013-04-05 | 2013-12-20 | 대동고려삼 주식회사 | The composition for improving antistress, antihyperlipidemia and antiobesity control using red ginseng extract powder, vitamins and minerals, and the health functional food |
KR20140007650A (en) * | 2012-07-10 | 2014-01-20 | 김영욱 | A fermentation red ginseng extract process |
KR101370386B1 (en) * | 2012-10-10 | 2014-03-06 | 서범구 | Preparation method of fermented red ginseng using effective micro-organisms |
KR101667284B1 (en) | 2015-05-12 | 2016-10-18 | 충남대학교산학협력단 | Cosmetics composition containing a fermented extract of black ginseng and herbal mixture |
-
2020
- 2020-05-19 KR KR1020200059945A patent/KR102436045B1/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100425022B1 (en) | 2002-01-05 | 2004-03-27 | 롯데제과주식회사 | Ginseng extract and pharmaceutical composition containing it |
KR100864471B1 (en) * | 2007-04-25 | 2008-10-20 | 김재경 | A processed ginseng using extract of herb medicine and a producing method thereof |
KR20140007650A (en) * | 2012-07-10 | 2014-01-20 | 김영욱 | A fermentation red ginseng extract process |
KR101370386B1 (en) * | 2012-10-10 | 2014-03-06 | 서범구 | Preparation method of fermented red ginseng using effective micro-organisms |
KR101343819B1 (en) | 2013-04-05 | 2013-12-20 | 대동고려삼 주식회사 | The composition for improving antistress, antihyperlipidemia and antiobesity control using red ginseng extract powder, vitamins and minerals, and the health functional food |
KR101667284B1 (en) | 2015-05-12 | 2016-10-18 | 충남대학교산학협력단 | Cosmetics composition containing a fermented extract of black ginseng and herbal mixture |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102490106B1 (en) * | 2022-09-13 | 2023-01-19 | 대동고려삼 주식회사 | Capsule product of red ginseng, Taekuksam, low temperature vacuum drying red ginseng using puffing and roasting and manufacturing process thereof |
Also Published As
Publication number | Publication date |
---|---|
KR102436045B1 (en) | 2022-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104873763A (en) | Health-care product for conditioning Qi deficiency constitution | |
CN107029146A (en) | A kind of clearing lung and eliminating phlegm air making-up and spleen enlivening supports Chinese medicine composition of lung and preparation method thereof | |
CN105695258A (en) | Female health wine containing lychee seed saponin | |
CN105901715A (en) | Deer glue cake and making method thereof | |
CN107019186A (en) | A kind of dietary supplement containing Bee Pollen | |
CN105454576A (en) | Jasmine-flower-comprising assorted Chinese herbal tea and preparation method thereof | |
KR20120056425A (en) | Health-supporting foods being effective the hairloss preventation or hair-growth and manufacturing method thereof | |
CN112167574A (en) | Fresh tortoise jelly and preparation method thereof | |
CN103652926A (en) | Food composition for tumor patients | |
CN103689559A (en) | Health-preserving health food formula beneficial for improving gastrointestinal functions and preparation method thereof | |
CN104398991A (en) | Medicinal composition for treating hypogalactia symptom of dairy cow and preparation method thereof | |
CN111184176A (en) | Instant health food composition for nine different constitutions based on theory of constitutions | |
KR102436045B1 (en) | Fermented black ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof | |
CN105232911A (en) | Traditional Chinese medicine composition | |
KR20160000695A (en) | Herbal-medicine containing dha for recovering fatigue and enhancing memory, and method of manufacturing the same | |
CN103734767A (en) | Health-care food | |
KR100780552B1 (en) | Milk for the baby comprising medicalherbs and method preparing thereof | |
KR101783549B1 (en) | Health supplement food containing dha for recovering fatigue, and method of manufacturing the same | |
CN108783432A (en) | Health food and preparation method thereof with antitumaous effect | |
KR102436041B1 (en) | Fermented red ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof | |
CN113144168A (en) | Method for preparing penis cervi pill | |
CN112807415A (en) | Spleen and stomach warming and tonifying middle-jiao tea and preparation method thereof | |
CN110613810A (en) | Traditional Chinese medicine composition for conditioning sub-health and preparation method thereof | |
CN110584037A (en) | Food ginseng cream and preparation method thereof | |
KR100815333B1 (en) | Healthfood using medicalherbs and method preparing thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |